<DOC>
	<DOCNO>NCT02111551</DOCNO>
	<brief_summary>This study plan learn whether nicotine-like investigational new drug , DMXB-A [ 3- ( 2,4-dimethoxybenzylidene ) anabaseine ] may positive effect mental focus may help u find new type treatment autism spectrum disorder . Subjects come screen visit three drug visit . There least one week drug visit allow drug eliminate system completely . During drug visit subject receive either placebo ( capsule look like medicine real ) , 75 mg DMXB-A , 150 mg DMXB-A . During drug day vital sign well monitor study physician . Subjects complete paper pencil tasks test memory , attention , speed , problem solving , rating scale questionnaire , study team record brain wave pattern electroencephalogram ( EEG ) .</brief_summary>
	<brief_title>Phase I Nicotinic Agonist Treatment Trial Autism</brief_title>
	<detailed_description />
	<mesh_term>Autistic Disorder</mesh_term>
	<mesh_term>Nicotinic Agonists</mesh_term>
	<mesh_term>3- ( 2,4-dimethoxybenzylidene ) anabaseine</mesh_term>
	<criteria>age 1850 meet DSM5 criterion Autism Spectrum Disorder , Levels 1 2 , define Autism Diagnostic Observation Schedule nonsmoking person good health person estimate verbal nonverbal IQ &lt; 70. abuse substance . Persons sufficiently fluent English permit test history severe head injury Fragile X Syndrome Rett Syndrome</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Autism</keyword>
	<keyword>Nicotinic agonist</keyword>
	<keyword>Cognition</keyword>
	<keyword>P50</keyword>
	<keyword>Alpha 7</keyword>
</DOC>